🇺🇸 FDA
Pipeline program

Olutasidenib

C-002102-003

Approved small_molecule active

Quick answer

Olutasidenib for AML (Acute Myeloid Leukemia) is a Approved program (small_molecule) at RIGEL PHARMACEUTICALS INC with 1 ClinicalTrials.gov record(s).

Program details

Company
RIGEL PHARMACEUTICALS INC
Indication
AML (Acute Myeloid Leukemia)
Phase
Approved
Modality
small_molecule
Status
active

Clinical trials